Barclays Reiterates CHF 80 Price Target for Novartis (VTX:NOVN)

Barclays set a CHF 80 price target on Novartis (VTX:NOVN) in a research report released on Friday, Borsen Zeitung reports. The firm currently has a sell rating on the stock.

NOVN has been the subject of several other research reports. Jefferies Financial Group upped their price target on Nice to $166.00 and gave the stock a buy rating in a research note on Thursday, May 16th. UBS Group restated a neutral rating on shares of CAIXABANK/ADR in a research note on Thursday. Deutsche Bank upped their price target on Union Pacific from $197.00 to $206.00 and gave the stock a buy rating in a research note on Friday. Morgan Stanley upped their price target on Intact Financial from C$125.00 to C$128.00 in a research note on Thursday, May 30th. Finally, Goldman Sachs Group started coverage on Enbridge in a research note on Thursday. They set a neutral rating for the company. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the stock. Novartis presently has an average rating of Hold and an average price target of CHF 88.64.

Novartis has a 52 week low of CHF 72.45 and a 52 week high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Recommended Story: How to interpret Moving Average Convergence Divergence (MACD)

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.